| Revenue | {{ Info.Revenue | formatUSD }} |
| Headquarters | {{ Info.Headquarters }} |
| Registration status | Registration Changed to AVIDITY PARTNERS MANAGEMENT LP |
|
Exempt Reporting Adviser
2B(3)- PF>150mn
act solely as an adviser to private funds but you are no longer eligible to check box 2.B.(2) because you have assets under management, as defined in rule 203(m)-1, in the United States of $150 million or more |
|
| Private Fund GAV* | 0 |
| SMA’s | No |
| Private Funds | 0 1 |
| Contact Info | 214 xxxxxxx |
| Stock Ticker | Stock Name | $ Position | % Position | $ Change | # Change |
|---|---|---|---|---|---|
| Stck Ticker252828108 | Stock NameDIANTHUS THERAPEUTICS INC | $ Position$126,084,640 | % Position29.00% | $ Change288.00% | # Change84.00% |
| Stck Ticker156944100 | Stock NameCG ONCOLOGY INC | $ Position$64,484,212 | % Position15.00% | $ Change65.00% | # Change7.00% |
| Stck Ticker101137107 | Stock NameBOSTON SCIENTIFIC CORP | $ Position$16,040,609 | % Position4.00% | $ Change-54.00% | # Change-49.00% |
| Stck TickerG5960L103 | Stock NameMEDTRONIC PLC | $ Position$18,152,744 | % Position4.00% | $ Change | # Change |
| Stck Ticker632307104 | Stock NameNATERA INC | $ Position$11,332,288 | % Position3.00% | $ Change-66.00% | # Change-65.00% |
| Stck Ticker687604108 | Stock NameORUKA THERAPEUTICS INC | $ Position$12,699,954 | % Position3.00% | $ Change222.00% | # Change88.00% |
| Stck Ticker110122108 | Stock NameBRISTOL-MYERS SQUIBB CO | $ Position$11,617,760 | % Position3.00% | $ Change | # Change |
| Stck Ticker21077P108 | Stock NameCONTEXT THERAPEUTICS INC | $ Position$8,701,621 | % Position2.00% | $ Change78.00% | # Change20.00% |
| Stck Ticker235851102 | Stock NameDANAHER CORPORATION | $ Position$10,844,822 | % Position2.00% | $ Change-39.00% | # Change-39.00% |
| Stck Ticker46489V302 | Stock NamePERSPECTIVE THERAPEUTICS INC | $ Position$10,269,533 | % Position2.00% | $ Change61.00% | # Change61.00% |